MedPath

Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Cancer
Registration Number
NCT00004884
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether docetaxel plus gemcitabine is more effective than docetaxel plus cisplatin in treating advanced pancreatic cancer.

PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel and gemcitabine with that of docetaxel and cisplatin in treating patients who have metastatic or locally advanced pancreatic cancer.

Detailed Description

OBJECTIVES: I. Assess the efficacy of docetaxel and gemcitabine vs docetaxel and cisplatin in patients with metastatic or locoregionally advanced pancreatic cancer. II. Assess the toxicity, response rate, duration of response, time to progression, survival, performance status, and weight associated with these treatment regimens in these patients.

OUTLINE: This is a randomized, open label, multicenter study. Patents are randomized to one of two treatment arms. Arm I: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and docetaxel IV over 1 hour on day 8. Arm II: Patients receive docetaxel IV over 1 hour followed by cisplatin IV over 1 hour on day 1. Treatment is repeated every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks until disease progression, and then every 8 weeks until death.

PROJECTED ACCRUAL: Up to 82 patients (41 per arm) will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
96
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (19)

Institut Jules Bordet

🇧🇪

Brussels, Belgium

Hopital Universitaire Erasme

🇧🇪

Brussels, Belgium

U.Z. Gasthuisberg

🇧🇪

Leuven, Belgium

National Cancer Institute of Egypt

🇪🇬

Cairo, Egypt

CHU Ambroise Pare

🇫🇷

Boulogne Billancourt, France

Centre Alexis Vautrin

🇫🇷

Vandoeuvre-les-Nancy, France

Institut Gustave Roussy

🇫🇷

Villejuif, France

Klinikum St. Marien

🇩🇪

Amberg, Germany

Universitaetsklinik und Strahlenklinik - Essen

🇩🇪

Essen, Germany

Klinikum der J.W. Goethe Universitaet

🇩🇪

Frankfurt, Germany

Scroll for more (9 remaining)
Institut Jules Bordet
🇧🇪Brussels, Belgium

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.